ADA
Financiado
Accelerating the Dissemination of Agluna R a clinically proven innovative silv...
Accelerating the Dissemination of Agluna R a clinically proven innovative silver ion based anti microbial surface technology from orthopaedics sector into the dental implant sector
The project objective is to confirm the commercial application of Agluna(R), an innovative silver ion based anti-microbial surface technology, to dental implants. Agluna(R) has already demonstrated a significant reduction in the i...
The project objective is to confirm the commercial application of Agluna(R), an innovative silver ion based anti-microbial surface technology, to dental implants. Agluna(R) has already demonstrated a significant reduction in the incidence of post-operative infection in clinical use within the EU limb salvage market, and is being actively commercialised within the wider global orthopaedic market.
Implant related infections are associated with the formation of biofilm on the surface of implanted devices. This is a global problem with socio-economic costs recognised across a range of medical device sectors. The dental implant sector is actively searching for solutions to the problem of post-operative implant infection (peri-implantitis). With growing concern about antibiotic-resistant bacterial strains, the subsequent expected outcome following this project is for Agluna(R) to become commercialised in EU/global markets as a differentiated, cost effective and clinically proven technology utilising silver ions, a well-known biocide with very limited reported bacterial resistance.
Phase 1 will confirm a business plan for successful commercialisation of Agluna(R) in the dental implant sector. We seek confirmation of:
- the size and scope of the EU and global market opportunity in the dental sector;
- competing approaches to prevention and control of post-operative infection in this sector;
- market entry strategy taking account of EU and other international regulatory pathways;
- investment requirements, time to market, and return on investment.
Phase 1 is six months in duration; the principal deliverable is a fully substantiated business plan. This will provide the basis for Phase 2, in which Agluna(R) will be piloted on a dental implant product that is designed, manufactured and clinically tested in a human proof of concept study.
ver más
Duración del proyecto: 6 meses
Fecha Inicio: 2015-01-28
Fecha Fin: 2015-07-31
Fecha Fin: 2015-07-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2015-07-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
Presupuesto
El presupuesto total del proyecto asciende a
71K€
Líder del proyecto
ACCENTUS MEDICAL LIMITED
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
439.35K€ |
Participante